MedTrace Logo

Prevelance of Axial Spondylosis Arthritis in Inflammatory Bowel Disease and Its RESPONSE to Tumour Necrosis Factor (TNF) Inhibitors Treatment in Assiut University Hospital

NCT06601595 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2024-09-19

No results posted yet for this study

Summary

Prevelance of axial spondylosis arthritis in inflammatory bowel disease and its RESPONSE to tumour necrosis factor (TNF) inhibitors TREATMENT

Conditions

  • Inflammatory Bowel Disease (IBD)
  • Spondylarthropathies
  • TNF-alpha Inhibitors

Interventions

DRUG

TNF inhibitors

tumour necrosis factor inhibitors approved as treatments for ulcerative colitis and/or Crohns disease

DRUG

conventional ibd medical treatment

Conventional therapies for ulcerative colitis and Crohns disease (CD) include aminosalicylates, corticosteroids, thiopurines, methotrexate other than anti-tumor necrosis factor agents.

Sponsors & Collaborators

  • Mohamed Nasr

    lead OTHER

Principal Investigators

  • Salwa salaheldin elgendi, professor doctor · Assiut University

  • hossam Mahmoud AbdulWahab, assistant professor · Assiut University

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-31
Primary Completion
2026-01-31
Completion
2026-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06601595 on ClinicalTrials.gov